The experience of using biguanides (metformin BMS) in patients with older non-insulin-dependent diabetes mellitus

Abstract

Efficacy and safety of metformin BMS are studied in patients aged 60-65 years. The drug effectively normalizes glycemia in patients with non-insulin-dependent diabetes mellitus: during 3-month follow-up the level of HbAj_c decreased by 1 % and the level of glycemia after overnight fasting by 1.5 mmol/liter. No clinically significant changes in the levels of liver transaminases, blood urea, creatinine, and lactate were noted in any of the patients. The incidence of side effects during therapy with metformin was low, 20%) patients complained of dyspeptic symptoms mainly at the beginning of treatment. Metformin BMS improved the cardiovascular status: it ameliorated the metabolic processes in the myocardium and coronary circulation. Treatment with metformin BMS is recommended for elderly patients thoroughly selected with due considerations for well-known contraindications for biguanides.